Sentence: Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma .
Drug combination annotation:
[{'class': 'POS', 'spans': ['ibrutinib', 'venetoclax'], 'is_context_needed': True}]